FGF23 inhibitor 13a (FGF23-IN-13a) is a ZINC13407541 analogue with enhanced drug-like properties, inhibits FGF23 with IC50 of 0.14 uM.
FGF23 inhibitor 13a exhibits greater effects to increase Npt2a and Npt2c message expression, consistent with higher serum phosphate levels in kidney of Hyp mice.
FGF23 inhibitor 13a demonstrates short- and long-term efficacy in blocking FGF23 end-organ effects in Hyp mice, a human homologue of XLH. FGF23 inhibitor 13a efficiently abrogates aberrant FGF23 signaling, corrects hypophosphatemia and aberrant 1,25(OH)2D levels, and improves both bone and renal gene expression profiles caused by elevated FGF23 levels in Hyp mice.
Physicochemical Properties
M.Wt
237.302
Formula
C16H15NO
Appearance
Solid
CAS No.
Storage
Solide Powder
-20°C 12 Months; 4°C 6 Months
In Solvent
-80°C 6 Months; -20°C 6 Months
Shipping
Solubility
10 mM in DMSO
Chemical Name/SMILES
(E)-2-((E)-4-methylstyryl)benzaldehyde oxime
References
1. Xiao Z, et al. Mol Pharmacol. 2022 Mar 26:MOLPHARM-AR-2021-000471.
